AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

val down = cteBaseTableSymbol { kSqlClient.createBaseQuery(ACL::class) { selections .add(table) }.unionAllRecursively { kSqlClient.createBaseQuery(ACL::class, it ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...

NEW HAVEN, Conn., September 03, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for ...

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – NEW HAVEN, Conn.--(BUSINESS ...

Abstract: Multi-modal image synthesis is crucial for obtaining complete modalities due to the imaging restrictions in reality. Current methods, primarily CNN-based models, find it challenging to ...